Patient-Reported Outcome Study of Project ECHO for ILD

NCT05450276 | Unknown

• 1 other identifier: ILDC-003
• Study Type: observational
• Target: 56
• Locations: 1 country
• Sites: 1

Brief Summary

The study will assess whether patients of providers participating in Project ECHO for ILD experience reduced stress, including financial stress, based on their ability to receive timely and local care and services, The study will employ nested mixed-method design at baseline, at 6 months and at 12 months to answer the study question.

Conditions

Interstitial Lung Disease

Keywords

Progressive Fibrosing Interstitial Lung Disease; Idiopathic Pulmonary Fibrosis; Interstitial Lung Disease Associated With Systemic Sclerosis; Myositis-Associated Interstitial Lung Disease; Sarcoidosis; Hypersensitivity Pneumonitis; Pulmonary Fibrosis

Outcome Measures

Primary Outcomes (2)

• Change in patients' stress level

  Assessed by the Perceived Stress Scale at baseline, 6 months, and at study end. The range of scores is 0-40, with higher scores indicating more appraised stress.

  Up to 18 months

• Patients' satisfaction of care

  Assessed by the Patient Satisfaction Survey, a self-report scale assessing patient experience and satisfaction with local ILD care, which is composed of 28 items rated on a Likert Scale and Yes/No grading; the summed items produce a single satisfaction score.

  Up to 18 months

Secondary Outcomes (1)

• Change in patients' perceptions regarding local ILD care

  Up to 18 months

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients of pulmonologists and primary care physicians who participate in Project ECHO for ILD.

You may qualify if:

• Confirmed diagnosis of interstitial lung disease
• Not be currently followed by an ILD specialist at an academic institution or must live more than 50 miles away from an academic ILD center

Sponsors & Collaborators

• Pulmonary Care and Research Collaborative Limited: lead
• Genentech, Inc.: collaborator

Study Sites (1)

Pulmonary Care and Research Collaborative, Ltd.

Boston, Massachusetts, 02130, United States

Location

MeSH Terms

Conditions

Lung Diseases, Interstitial; Idiopathic Pulmonary Fibrosis; Sarcoidosis; Alveolitis, Extrinsic Allergic; Pulmonary Fibrosis

Condition Hierarchy (Ancestors)

Lung Diseases; Respiratory Tract Diseases; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Hypersensitivity, Delayed; Hypersensitivity; Immune System Diseases; Respiratory Hypersensitivity; Hypersensitivity, Immediate; Fibrosis; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Aliaa Barakat, PhD

  Pulmonary Care and Research Collaborative, Ltd.

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 30, 2022
• First Posted: July 8, 2022
• Study Start: July 1, 2022
• Primary Completion: December 1, 2023
• Study Completion: March 1, 2024
• Last Updated: July 8, 2022

Record last verified: 2022-07

Locations

US (1)